KRAS and pancreatic neoplasm: Recognizing that 95% of PC cases exhibit mutant KRAS protein [19] and that KRAS-transformed cells have been shown to have enhanced macropinocytosis [20], it was anticipated that the peptide-linked arsenic compound might also target pancreatic cancers and increase the inhibition of ATO.